✦ LIBER ✦

36 Clinical phase I and II trial of cis platinum (CDDP) and preclinical and clinical phase I studies of malonato platinum (MDP)

✍ Scribed by Mathé, G.; Hayat, M.; Giralt, E.; Szpirglas, H.; Bayssas, M.; Gouveia, J.; Ribaud, P.; Misset, J.L.; Machover, D.

Book ID: 122845047
Publisher: Elsevier Science
Year: 1978
Tongue: English
Weight: 99 KB
Volume: 60
Category: Article
ISSN: 0300-9084
DOI: 10.1016/S0300-9084(78)80626-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I/II trials of WR-2721 and cis-pla

Phase I/II trials of WR-2721 and cis-platinum

✍ Donna Glover; John H. Glick; Clare Weiler; Kevin Fox; Andrew Turrisi; Morton M. 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 528 KB

Phase I trials of WR-2721 and cis-platin

Phase I trials of WR-2721 and cis-platinum

✍ Donna Glover; John H. Glick; Clare Weiler; John Yuhas; Morton M. Kligerman 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 477 KB

A Phase I clinical and pharmacological s

A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)

✍ Beale, P; Judson, I; O'Donnell, A; Trigo, J; Rees, C; Raynaud, F; Turner, A; Sim 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 123 KB

Phase I clinical trial of combined thera

Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and cis-platinum (II) diaminedichloride (NSC 119875)

✍ Richard A. Ellerby; Hugh L. Davis Jr.; Fred J. Ansfield; Guillermo Ramirez 📂 Article 📅 1974 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB

Thirty-one loading courses of 5-FU and cis-platinum (11) diaminedichloride (CPD) were given to 27 patients with a variety of malignancies. Up to 16 mg/kg/day of 5-FU and 2.5 mg/kg of the platinum were reached with minimal toxicity. Nausea (27/31) and vomiting (23/31) were the most frequent symptoms,

Preclinical and clinical overview of the

Preclinical and clinical overview of the novel platinum complex, ZD0473 (cis-amminedichloro[2-methylpyridine] platinum[II])

✍ Kelland, L; Judson, I; Koehler, M; Stevens, T; Roberts, D 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 116 KB

Phase I-II trial of percutaneous intra-a

Phase I-II trial of percutaneous intra-arterial Cis-diamminedichloro platinum (II) for regionally confined malignancy

✍ D. B. Calvo III; Y. Z. Patt; S. Wallace; V. P. Chuang; R. S. Benjamin; J. D. Pri 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 539 KB

Forty-nine patients with regionally confined recurrent malignancy were treated with intra-arterial cisdiamminedichloro platinum I1 in a Phase 1-11 trial. A safe starting dose of 120 mg/m\* was established. An overall response rate of 45% was noted with significant responses observed among patients w